Puma Biotechnology (PBYI -5.5%) is down, albeit on below-average volume, in apparent response to disparaging comments
on Twitter from Presidential hopeful Sen. Bernie Sanders (I-VT) about
its 20% price hike on breast cancer med Nerlynx (neratinib).
https://seekingalpha.com/news/3505061-puma-bio-6-percent-sanders-callout-nerlynx-price-hike
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.